• Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms 

      Janson, Eva Tiensuu; Knigge, Ulrich; Dam, Gitte; Federspiel, Birgitte; Grønbaek, Henning; Stålberg, Peter; Langer, Seppo W.; Kjaer, Andreas; Arola, Johanna; Schalin-Jäntti, Camilla; Sundin, Anders; Welin, Staffan; Thiis-Evensen, Espen; Sorbye, Halfdan (Journal article; Peer reviewed, 2021)
      Background The diagnostic work-up and treatment of patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) has undergone major advances and new methods are introduced. Furthermore, an update of the WHO ...
    • Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study 

      Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan; Grozinsky-Glasberg, Simona; Ahmadzadehfar, Hojjat; Grana, Chiara Maria; Zandee, Wouter T.; Cwikla, Jaroslaw; Walter, Martin A.; Oturai, Peter Sandor; Rinke, Anja; Weaver, Andrew; Frilling, Andrea; Gritti, Sara; Arveschoug, Anne Kirstine; Meirovitz, Amichay; Knigge, Ulrich; Sorbye, Halfdan (Peer reviewed; Journal article, 2019)
      Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms ...